ORG 34517

Drug Profile

ORG 34517

Alternative Names: ORG-34517; SCH-900636

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Organon
  • Developer Merck & Co; Organon; Pop Test
  • Class Antidepressants; Antineoplastics; Benzodioxoles; Chemosensitisers; Diagnostic agents; Phenanthrenes; Steroids
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Breast cancer
  • Discontinued Major depressive disorder

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral, Injection)
  • 25 Oct 2011 ORG 34517 is available for licensing as of 25 Oct 2011.
  • 25 Oct 2011 Pop Test acquires ORG 34517 from Merck & Co.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top